Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial
Latest Information Update: 08 May 2025
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 30 Apr 2025 Planned End Date changed from 31 Jan 2025 to 31 Jul 2025.
- 11 Dec 2024 Planned End Date changed from 1 Jul 2024 to 31 Jan 2025.
- 24 Feb 2022 Planned End Date changed from 1 Mar 2021 to 1 Jul 2024.